Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement Don HusereauMichael DrummondElizabeth Loder OriginalPaper 26 March 2013 Pages: 361 - 367
Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al. Pieter van BaalDavid MeltzerWerner Brouwer Commentary 18 April 2013 Pages: 369 - 373
The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.” Daniel T. GrimaLisa M. BernardDavid C. Mendelssohn Correspondence 11 April 2013 Pages: 375 - 376
Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia Michael J. SorichMichael D. WieseBrita Pekarsky Leading Article 09 April 2013 Pages: 377 - 391
Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing Simon EckermannAndrew R. Willan Review Article 26 March 2013 Pages: 393 - 401
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma Janette GreenhalghAdrian BagustPatrick Chu Review Article Open access 11 April 2013 Pages: 403 - 413
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal Nigel ArmstrongManuela JooreRob Riemsma Review Article 12 April 2013 Pages: 415 - 425
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States Kit N. SimpsonPamela P. PeiJ. Jaime Caro Original Research Article 26 April 2013 Pages: 427 - 444
The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies Rodrigo Refoios CamejoClare McGrathFrans Rutten Original Research Article 10 April 2013 Pages: 445 - 454
